442910-91-0

Basic information

• Product Name: 1H-Indole,7-fluoro-5-methyl-(9CI)
• Synonyms: 1H-Indole,7-fluoro-5-methyl-(9CI);7-fluoro-5-methyl-1H-indole;1H-Indole, 7-fluoro-5-methyl-;EOS-61944
• CAS NO: 442910-91-0
• Molecular Formula: C₉H₈FN
• Molecular Weight: 149.17
• Product Categories: HALIDE
• Mol File: 442910-91-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Indole,7-fluoro-5-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole,7-fluoro-5-methyl-(9CI)(442910-91-0)
• EPA Substance Registry System: 1H-Indole,7-fluoro-5-methyl-(9CI)(442910-91-0)

Safety Data

• Hazardous Substances Data: 442910-91-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Indole,7-fluoro-5-methyl-(9CI) is used as a key intermediate in the synthesis of various drugs and bioactive molecules for the treatment of different diseases. Its unique structure and biological activities contribute to the development of novel therapeutic agents.
Used in Medicinal Chemistry Research:
As a heterocyclic aromatic compound, 1H-Indole,7-fluoro-5-methyl-(9CI) is utilized in medicinal chemistry research to explore its potential applications in treating various diseases. Its antimicrobial, anticancer, and anti-inflammatory properties make it a promising candidate for further investigation and development.
Used in Drug Development:
1H-Indole,7-fluoro-5-methyl-(9CI) is employed in drug development for its potential therapeutic applications. Ongoing studies aim to uncover its pharmacological properties and evaluate its efficacy in treating specific conditions, thereby contributing to the advancement of new treatment options.

Upstream product

• 446-34-4 2-fluoro-4-methyl-1-nitrobenzene 
• 1826-67-1 vinyl magnesium bromide 
• 18349-09-2 2-bromo-6-fluoro-4-methyl aniline 
• 1066-54-2 trimethylsilylacetylene 
• 1041693-61-1 1-(2-amino-3-fluoro-5-methylphenyl)-2-chloroethanone 
• 452-80-2 2-fluoro-4-methylaniline 
• 1403878-67-0 7-fluoro-5-methyl-2-(trimethylsilyl)-1H-indole 
• 217314-44-8 2-fluoro-6-iodo-4-methylaniline 
• 1403878-71-6 C₁₂H₁₄FNO 
• 1403878-72-7 2-ethynyl-6-fluoro-4-methylaniline 

Downstream Products

• 1234779-88-4 7-fluoro-5-methyl-1-[(4-nitrophenyl)sulfonyl]-1H-indole 
• 1403878-69-2 ethyl N-({4-[(1R,2S)-1-(4-chlorophenyl)-1-{7-fluoro-5-methyl-1-[(4-nitrophenyl)sulfonyl]-1H-indol-3-yl}pentan-2-yl]phenyl}carbonyl)-β-alaninate 
• 1234779-91-9 C₃₇H₃₅ClFN₃O₇S 
• 1234779-89-5 4-[(1R,2S)-1-(4-chlorophenyl)-1-{7-fluoro-5-methyl-1-[(4-nitrophenyl)sulfonyl]-1H-indol-3-yl}pentan-2-yl]benzoic acid 
• 887338-57-0 3-bromo-7-fluoro-5-methyl-1-tosyl-1H-indole 

Relevant articles and documents

Direct Formic Acid Mediated Z-Selective Reductive Coupling of Dienes and Aldehydes

Methods for the addition of unsaturated nucleophiles to carbonyls to generate Z-olefin products remain rare and often require either alkyl borane or zinc reductants, limiting their utility. Demonstrated here is that formic acid mediates the Rh-catalyzed,

INDOLES FOR USE IN INFLUENZA VIRUS INFECTION

The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

Asymmetric synthesis of a glucagon receptor antagonist via friedel-crafts alkylation of indole with chiral α-phenyl benzyl cation

Development of a practical asymmetric synthesis of a glucagon receptor antagonist drug candidate for the treatment of type 2 diabetes is described. The antagonist consists of a 1,1,2,2-tetrasubstituted ethane core substituted with a propyl and three aryl groups including a fluoro-indole. The key steps to construct the ethane core and the two stereogenic centers involved a ketone arylation, an asymmetric hydrogenation via dynamic kinetic resolution, and an anti-selective Friedel-Crafts alkylation of a fluoro-indole with a chiral α-phenyl benzyl cation. We also developed two new efficient syntheses of the fluoro-indole, including an unusual Larock-type indole synthesis and a Sugasawa-heteroannulation route. The described convergent synthesis was used to prepare drug substance in 52% overall yield and 99% ee on multikilogram scales.

CRYSTALLINE POLYMORPHIC FORMS OF AN ANTIDIABETIC COMPOUND

The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included.

1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME

A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D